What it's for (Indications)
- Cetrorelix, a synthetic decapeptide, is specifically indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation (COS) as part of assisted reproductive technologies (ART), such as in vitro fertilization (IVF).
- By effectively blocking the endogenous LH surge, cetrorelix helps optimize the timing of oocyte retrieval, thereby maximizing the chances of successful fertilization and implantation.
- Its utility lies in providing precise control over the ovarian cycle, preventing spontaneous ovulation that could compromise the ART procedure, ensuring follicles reach optimal maturity before retrieval.
- This controlled approach significantly enhances the predictability and success rates of ART cycles.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Cetrorelix is administered via subcutaneous injection. Two primary dosing regimens are typically employed to prevent premature LH surges. The multiple-dose regimen involves a daily subcutaneous injection of 0.25 mg, starting on day 5 or 6 of ovarian stimulation (after sufficient follicular development is observed) and continuing daily until the day of human chorionic gonadotropin (hCG) administration. Alternatively, a single-dose regimen of 3 mg may be administered, typically around day 7 or 8 of stimulation, with the understanding that the gonadotropin-suppressing effects of this single dose are maintained for approximately 4 days. The exact initiation and duration of therapy are determined by the treating physician based on individual patient response to ovarian stimulation, serum estradiol levels, and ultrasound monitoring of follicular growth. Patients should be carefully instructed on proper self-administration techniques, or the injection should be performed by a healthcare professional, ensuring aseptic technique and rotation of injection sites. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with cetrorelix administration primarily include transient and generally mild injection site reactions, such as redness, itching, swelling, or bruising at the site of injection.
- These local reactions are typically self-resolving and do not usually necessitate discontinuation of treatment.
- Systemic side effects, though less common, can include headaches, nausea, and mild abdominal discomfort.
- More serious but rare adverse events include systemic allergic or pseudo-allergic reactions, ranging from rash, pruritus, and urticaria to severe, potentially life-threatening anaphylactic reactions, which require immediate medical attention and discontinuation of the drug.
- As cetrorelix is used in the context of controlled ovarian stimulation, patients are also at an inherent risk for ovarian hyperstimulation syndrome (OHSS), a known complication of ART, which can range from mild to severe and may necessitate hospitalization and intensive medical management, including fluid and electrolyte balance monitoring and thromboprophylaxis.
Serious Warnings
- Black Box Warning: **Serious Warnings:** While cetrorelix does not carry an FDA-mandated Black Box Warning, healthcare providers and patients must be fully aware of several serious potential risks associated with its use, particularly concerning severe hypersensitivity reactions. Anaphylaxis or anaphylactoid reactions, although rare, have been reported following cetrorelix administration, even with the first dose. These reactions can be life-threatening and necessitate immediate medical intervention, including resuscitation measures such. Patients should be informed about the signs and symptoms of a severe allergic reaction (e.g., difficulty breathing, swelling of the face, lips, tongue, or throat, generalized urticaria, dizziness, or lightheadedness) and instructed to seek emergency care immediately if they occur. Furthermore, while cetrorelix helps prevent premature ovulation, it is used within the context of controlled ovarian stimulation, which carries an inherent and significant risk of Ovarian Hyperstimulation Syndrome (OHSS). Severe OHSS can be a life-threatening condition characterized by profound ovarian enlargement, ascites, pleural effusion, electrolyte imbalances, hemoconcentration, and potential for thromboembolic events, requiring vigilant monitoring and expert management during and after treatment.
- Patients receiving cetrorelix should be closely monitored for signs of hypersensitivity reactions, especially after the first dose, given the potential for systemic allergic responses, including anaphylaxis.
- Individuals with a known history of severe allergic reactions, asthma, or other allergic conditions should exercise extreme caution, and appropriate emergency measures (e.
- g.
- , epinephrine, antihistamines, corticosteroids) should be readily available.
- The risk of ovarian hyperstimulation syndrome (OHSS) is an inherent and significant concern with controlled ovarian stimulation; while cetrorelix helps to control the ovarian cycle, it does not eliminate the risk of OHSS, which can be severe, life-threatening, and may lead to serious complications such as thromboembolic events, acute renal failure, and acute respiratory distress syndrome.
- Caution is advised in patients with pre-existing hepatic or renal impairment, as the pharmacokinetics of cetrorelix in these populations have not been extensively studied, and drug accumulation could theoretically occur.
- Cetrorelix should not be used in pregnant or lactating women due to potential harm to the fetus or infant.
How it Works (Mechanism of Action)
Cetrorelix is a potent, competitive antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It acts by binding to the GnRH receptors located on the surface of the anterior pituitary gland cells, thereby blocking the downstream signaling pathway that leads to the pulsatile release of endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. Unlike GnRH agonists, which initially cause a transient surge in gonadotropins before desensitization, cetrorelix induces an immediate and dose-dependent suppression of gonadotropin secretion. This rapid and direct antagonistic action effectively prevents the premature LH surge that can occur during controlled ovarian stimulation, thus preventing premature ovulation and allowing for the controlled maturation of ovarian follicles and timely oocyte retrieval in women undergoing assisted reproductive technologies. The suppression is reversible upon discontinuation of the drug.
Commercial Brands (Alternatives)
No other brands found for this formula.